Zoetis INC 8-K filings

Zoetis reported flat Q2 2026 revenue of $2.5 billion and revised its full-year guidance downwards, citing a pressured Companion Animal market and increased competition.

Zoetis Inc. announced a quarterly dividend of $0.53 per share for the third quarter of 2026, payable on September 1, 2026.

Zoetis reported first quarter 2026 results with revenue of $2.3 billion, a 3% increase, and revised full-year guidance amidst a challenging operating environment.

Zoetis Inc. announced solid financial results for the fourth quarter and full year 2025, alongside optimistic guidance for 2026, driven by portfolio strength and innovation.

Zoetis Inc. announced its Board of Directors declared a $0.53 per share dividend for the second quarter of 2026, payable on June 2, 2026.

Zoetis Inc. completed a $2.0 billion private offering of 0.25% Convertible Senior Notes due 2029, with net proceeds primarily allocated to fund capped call transactions and repurchase approximately $1.8 billion of common stock.

Zoetis Inc. announced its Board of Directors declared a first-quarter 2026 dividend of $0.53 per share, representing a 6% increase from the previous year.

Zoetis Inc. outlined its robust R&D pipeline and strategic vision to capitalize on the expanding $90 billion global animal health market by 2035.

Zoetis reported third-quarter 2025 revenue of $2.4 billion, a 1% increase, with net income rising 6% to $721 million, while revising full-year revenue guidance.

Zoetis Inc. announced the appointment of Stephanie Tilenius, a seasoned digital health and AI entrepreneur, to its Board of Directors, effective December 1, 2025.

Zoetis Inc. announced a $0.50 per share dividend for the fourth quarter of 2025, payable on December 2, 2025.

Zoetis Inc. has entered into a new five-year, $1.25 billion senior unsecured revolving credit facility, replacing its existing agreement and enhancing financial flexibility.

Zoetis Inc. has successfully issued $1.85 billion in new senior notes across two tranches, strengthening its financial position.

Zoetis Inc. reported strong second quarter 2025 financial results, exceeding expectations with 8% organic operational revenue growth and raising its full-year 2025 guidance.

Zoetis Inc. announces the election of Dr. Mark Stetter to its Board of Directors and reports the results of its 2025 Annual Meeting of Shareholders, including the approval of executive compensation and the ratification of KPMG LLP as the company's independent auditor.

Zoetis Inc. (NYSE:ZTS) announces a dividend of $0.50 per share for the third quarter of 2025, payable on September 3, 2025, to shareholders of record as of July 18, 2025.

Zoetis announces a 1% revenue increase to $2.2 billion and a 5% net income increase to $631 million for Q1 2025, while updating its full-year revenue guidance to $9.425 $9.575 billion.

Zoetis announces a 5% revenue increase to $2.3 billion for Q4 2024 and provides full year 2025 revenue guidance of $9.225 $9.375 billion.

Zoetis Inc. announces a dividend of $0.50 per share for the second quarter of 2025, payable on June 3, 2025, to shareholders of record as of April 21, 2025.

Zoetis presented at the J.P. Morgan Healthcare Conference, showcasing strong 2024 performance, diverse growth drivers, and a robust pipeline for future expansion.

Zoetis has declared a first quarter 2025 dividend of $0.50 per share, marking a 16% increase from the previous quarterly rate.

Zoetis has appointed Jamie Brannan as Chief Commercial Officer in a leadership restructure aimed at accelerating long-term growth and optimizing global commercial operations.

Zoetis announced strong third-quarter 2024 results, with revenue reaching $2.4 billion and net income of $682 million, and raised its full-year 2024 guidance.

Zoetis Inc. has declared a fourth-quarter dividend of $0.432 per share, payable on December 3, 2024, to shareholders of record as of October 31, 2024.

Zoetis announced an 8% increase in revenue to $2.4 billion and a 7% decrease in net income to $624 million for the second quarter of 2024, while also raising its full-year guidance.

Zoetis has authorized a new $6 billion share repurchase program, demonstrating confidence in its cash flow and commitment to returning capital to shareholders.

Zoetis Inc. has announced a transition agreement with executive Heidi Chen, who will move from her current role to a consultant position after a transition period.

Zoetis Inc. held its 2024 Annual Meeting, where shareholders approved an officer exculpation amendment and elected directors, while also noting the retirement of Dr. Linda Rhodes from the Board.

Zoetis has declared a third quarter 2024 dividend of $0.432 per share, payable on September 4, 2024, to shareholders of record as of July 18, 2024.

Zoetis announced a 10% increase in revenue and a 9% increase in net income for the first quarter of 2024, along with an updated and increased full-year guidance.